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Patients can experience acute kidney injury and require renal
replacement therapy at any time during their admission to
intensive care units. Prognostic scores have been used to
characterize and stratify patients by the severity of acute
disease, but scores based on findings during the day of
admission may not be reliable surrogate markers of the
severity of acute illness in this population. The aim of this
study was to evaluate the performance of SAPS 3 and
MPM0-III scores, determined at the start of renal replacement
therapy, in 244 patients admitted to 11 units of three
hospitals in Rio de Janeiro, Brazil. Continuous renal
replacement therapy was used as first indication in 84% of
these patients. Discrimination by area under the receiver
operating characteristic curve was significantly better for
SAPS 3 than for MPM0-III, as was the calibration measured
by the Hosmer–Lemeshow goodness-of-fit test. Mortality
prediction and calibration approached those eventually
found when a customized equation of SAPS 3 for Central and
South America was used. After adjusting for other relevant
covariates in multivariate analyses, both higher prognostic
scores and length of stay in the unit prior to the start of renal
replacement therapy were the main predictive factors for
hospital mortality. Our study shows that a customized SAPS 3
model was accurate in predicting mortality and seems a
promising algorithm to characterize and stratify patients in
clinical studies.
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Acute kidney injury (AKI) is a severe and frequent
complication in patients admitted to intensive care units
(ICU) and is associated with high mortality rates, especially
when renal replacement therapy (RRT) is required.1–5
Patients with AKI are usually included in clinical studies at
the moment they fulfill a predefined criterion for the
diagnosis of AKI (generally, based on changes in serum
creatinine levels and/or urine output) or at the start of RRT.
The outcomes of these patients are dependent on several
characteristics other than the severity of AKI itself, including
the severity of acute illness.1,2,4,6,7
Despite their limitation in inaccurately predicting indivi-
dual outcomes, prognostic scores have been used to
characterize and stratify patients in terms of severity of acute
disease in clinical studies performed in an intensive care
setting. Moreover, these models are useful to assist physicians
in discussions about prognosis and in clinical decision-
making to improve allocation of resources in intensive care.8
However, general prognostic scores used in critical care do
not perform well in patients with AKI and tend to
underestimate the risk of mortality.9–12 Usually, these scores
were developed taking into consideration data available at
admission or within the first 24 h of ICU.13–18 The ability of
AKI-specific scores in predicting outcomes was shown to be
similarly poor.11,12,19–23
Few years ago, the third versions of the Simplified Acute
Physiology Score (SAPS 3)16 and the Mortality Probability
Models (MPM0-III)
18 were developed and validated world-
wide.24–28 In both scores, data collected at the moment of
ICU admission are used to estimate the risk for hospital
death.16,18 Recently, Tsai et al.29 showed that the SAPS 3 at
the start of RRT was the best risk adjustment system to
predict mortality in patients supported by extracorporeal
membrane oxygenation and acute dialysis. As patients can
experience AKI and/or require RRT at any time during the
ICU stay, scores estimated solely within the first day of ICU
may not be reliable surrogate markers of severity of acute
http://www.kidney-international.org o r ig ina l a r t i c l e
& 2010 International Society of Nephrology
Received 18 June 2009; revised 3 August 2009; accepted 11 August
2009; published online 7 October 2009
Correspondence: Elizabeth Maccariello, Department of Nephrology, Uni-
versidade Federal Fluminense, Hospital Universita´rio Antoˆnio Pedro, Rua
Jardim Botaˆnico, 674 – Sala 405, Rio de Janeiro 22461-000, Brazil.
E-mail: emaccariello@yahoo.com.br
Kidney International (2010) 77, 51–56 51
illness in this population. Therefore, the aim of this study was
to validate the SAPS 3 and MPM0-III scores using data from
the start of RRT in patients with AKI.
RESULTS
During the study period, 286 patients received RRT in the
participating ICUs. Out of them, 244 (85%) fulfilled the
eligibility criteria and were analyzed in the study. Patients’
sources of ICU admission were: emergency department
[n¼ 166 (68%)], operating room [n¼ 47 (19%)] and wards
[n¼ 31 (13%)]. The main clinical characteristics at ICU
admission are shown in Table 1.
AKI with need of RRT ensued after a median 3 (1–13) days
after ICU admission. The main contributing factors for AKI
were ischemia/shock (75%), sepsis (74%), contrast/nephro-
toxins (33%), rhabdomyolysis (5%) and urinary tract
obstruction (2%) (a patient could have more than one
contributing factor). Eighty-nine (36%) patients received
RRT on the first day of ICU and 155 (65%) thereafter.
Continuous RRT was used in 206 (84%) patients. The main
renal-related and laboratory data at the start of RRT are
depicted in Table 2.
The ICU mortality was 63% (153/244) and hospital
mortality was 68% (167/244). The main outcome data are
reported in Table 1. At the start of RRT, the SAPS 3 score was
70.0±13.0 (range: 38–106) points. As expected SAPS 3 score
were higher in decedents than in survivors (74.5±11.6 vs
60.4±10.4, Po0.001). Performances of the models are
presented on Table 3. Discrimination was superior
(P¼ 0.001) and calibration was relatively better for the SAPS
3 than for the MPM0-III score. Both the general equation of
SAPS 3 and especially the MPM0-III score tended somewhat
to underestimate the observed mortality (standardized
mortality rate (SMR) 41). However, when the customized
equation of SAPS 3 for countries from Central and South
America (CSA) was used, the predicted mortality was closer
to the observed mortality (Table 3). Calibration curves of the
SAPS 3 and MPM0-III scores are shown in Figure 1.
Finally, we performed multivariate analyses to assess the
independent effect of the prognostic scores on hospital
mortality adjusting for the length of ICU stay before RRT, the
RIFLE classification, the use of vasopressors, the need for
mechanical ventilation, sepsis, comorbidities, chronic health
status and previous chronic renal failure. Two models were
fitted, containing either the SAPS 3 or MPM0-III score
(Table 4). Besides the prognostic scores, the number of ICU
days before RRT was the most important outcome predictor.
In the model containing the MPM0-III score, the use of
vasopressors and the presence of comorbidity conditions
were also associated with increased hospital mortality. Both
models had good calibration and discrimination. The
adjusted model containing the MPM0-III score improved
discrimination and calibration compared with the isolated
use of the prognostic score, but not the model containing
SAPS 3 score (Figure 2).
DISCUSSION
In this study, we have shown that the MPM0-III and SAPS 3
scores estimated at the start of RRT were independently
associated with hospital mortality in patients with AKI. In
Table 1 |Main patients’ demographic and clinical
characteristicsa
Variables
Variables at ICU admission
Age (years) 69.5±16.6
Male sex 140 (57%)
Poor chronic health status (Knaus C or D) 96 (39%)
Charlson Comorbidity Index (points)b 3 (1–5)
Main comorbidities
Arterial hypertension 167 (68%)
Congestive heart failure 90 (37%)
Diabetes mellitus 68 (28%)
Malignancy 61 (25%)
Coronary artery disease 56 (23%)
Chronic pulmonary disease 28 (12%)
Type of admission
Medical 197 (81%)
Scheduled surgical 22 (9%)
Emergency surgical 25 (10%)
Hospital stay before ICU admission (days) 0 (0–0)
Variables at the start of RRT
SAPS 3 (points) 70.0±13.0
SOFA on day 1 of RRT (except renal points) 8.3±3.4
Sepsis 180 (74%)
Mechanical ventilation 197 (81%)
Vasopressors 183 (75%)
Outcome variables
Length of ICU stay (days) 23 (9–41)
Length of hospital stay (days) 29 (15–54)
Decision to withhold/withdraw treatment 94 (39%)
ICU mortality 153 (63%)
Hospital mortality 167 (68%)
AKI, acute kidney injury; ESRD, end-stage renal disease; ICU, intensive care unit; IQR,
interquartile range; SAPS, Simplified Acute Physiology Score; SOFA, Sequential
Organ Failure Assessment.
aResults expressed as mean±s.d., median (IQR), n (%).
bCharlson Comorbidity Index minus points attributed to chronic renal failure.
Table 2 |Main patient renal-related and laboratory data at
the start of RRTa
Variables
RIFLE categories
Risk 39 (16%)
Injury 46 (19%)
Failure 159 (65%)
ICU stay before start of RRT (days) 3 (1–13)
Initial RRT modalities
Daily conventional dialysis 35 (14%)
Daily sustained low-efficiency dialysis 3 (1%)
Continuous RRT 206 (84%)
Serum creatinine at ICU admission (mg/dl) 1.9 (1.2–2.8)
Serum urea at ICU admission (mg/dl) 110 (65–172)
Urinary output (ml/day) 490 (256–810)
Serum bicarbonate concentration (mEq/l) 18.7 (15.8–22.0)
AKI, acute kidney injury; RRT, renal replacement therapy.
aResults expressed as mean±s.d., median (IQR), n (%).
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accordance to previous studies, mortality was also dependent
on the burden of comorbidities, time to the start of RRT and
need for vasopressors.1,2,4,5,30 On the other hand, patients
with acute on chronic kidney injury had higher survival
rates.5 Furthermore, the SAPS 3 score, in particular the
customized equation for CSA, was able to accurately predict
the outcome in this population, whereas the MPM0-III had a
relatively worse calibration and tended to significantly
underestimate mortality, despite a reasonable discrimination.
The MPM0-III score is the last updated version of the
Mortality Probability Models and was developed using data
from 124,855 patients admitted to 135 American ICUs
participating in Project IMPACT.18 In contrast, the SAPS 3
study was conducted at 307 ICUs from 35 countries and
enrolled almost 20,000 patients.16 One important particular-
ity of this score was the derivation of seven customized
equations to improve the precision of estimations for
different geographic regions of the world.16 Both scores are
composed by easily available clinical variables at the time of
ICU admission (±1 h) and were extensively validated in
subsequent studies in critically ill patients.24–28
Four major reasons prompted us to expect a good
performance of these scores at the start of RRT. First, the
severity of acute illness and physiological derangements are
major determinants of outcomes and key elements to stratify
patients with AKI in clinical studies.1,2,4,6,7 Second, prog-
nostic scores are traditionally used to characterize the severity
of the disease, but unhelpful for predicting the outcome in
patients with AKI when calculated at ICU admission.12,19–23
Third, the time since hospital or ICU admission to the
development of AKI or the requirement of RRT is directly
associated with mortality,1,5–7 and this aspect was clearly
shown in this study. And finally, sequential evaluation of
predictive models have shown better models’ performance
when the estimation was made at the nephrology consulta-
tion or at the start of RRT.9,10,29 In the first study testing this
hypothesis, Tsai et al.29 have evaluated five different scores at
ICU admission and at the commencement of dialysis in 104
patients supported with extracorporeal membrane oxygena-
tion. They showed that the SAPS 3 score estimated when RRT
was needed had the best discriminative ability and calibration
despite a trend to underestimate mortality in low-risk
patients. In our study, discrimination was good for both
models (area under receiver-operating characteristic curve
(AROC) 0.73 for MPM0-III and 0.82 for SAPS 3; P¼ 0.001).
However, calibration was borderline for the MPM0-III.
Indeed, the use of a customized equation resulted in
improved calibration of SAPS 3 and corrected the tendency
to underestimate mortality observed when the standard
equation was used, thus resulting in SMR closer to the unit
(Table 3). To our knowledge, there is not a conventional
method of comparing goodness-of-fit w2 tests, but it seems
that this statistics was considerably lower for the SAPS 3
score. This can be better perceived in the calibration curves
that showed clearly significant underestimation in practically
all of the strata of predicted mortality using the MPM0-III
score. Nevertheless, the lines of observed mortality for the
SAPS 3 score (specially the customized equation for CSA)
were closer to the line of equality. As depicted in Figure 2, the
SAPS 3-CSA correlated accurately with hospital mortality
throughout the strata of predicted mortality. To our knowl-
edge, this is the first validation of MPM0-III score in patients
with AKI.
Our study has potential limitations to be taken into
account in the generalization of our results. Patients were
selected from three general tertiary care hospitals. However,
we cannot rule out possible selection biases concerning
regional specificities related to standards of care, including
criteria used to start dialysis, implement end-of-life decisions
and ICU admission/discharge policies. Although we have
evaluated a relatively high number of patients requiring RRT,
Table 3 | Area under receiver-operating characteristic curves, Hosmer–Lemeshow goodness-of-fit C-statistics and standardized
mortality ratios for the MPM0-III, SAPS 3, and customized SAPS 3 scores (n=244)
ROC curve Goodness-of-fit C-test
Prognostic score AROC±s.e. CI 95% v2 P-value Predicted mortalitya (mean±s.d.) SMR (CI 95%)
MPM0-III 0.73±0.03 (0.66–0.80) 14.910 0.061 28.2±14.7 2.42 (1.95–3.01)
SAPS 3 (GEq) 0.82±0.03 (0.76–0.88) 10.160 0.254 54.0±21.8 1.26 (1.10–1.46)
SAPS 3 (CSA) 0.82±0.03 (0.76–0.88) 9.330 0.315 65.7±22.4 1.04 (0.92–1.18)
AROC, area under receiver operating characteristic curve; CI, confidence interval; GEq, general equation; CSA, customized equation for countries from Central and South
America; SAPS, Simplified Acute Physiology Score; SMR, standardized mortality rate.
aThe observed hospital mortality was 68.4%.
100
90
80
70
60
50
40
30
20
10
0
H
os
pi
ta
l m
or
ta
lit
y 
(%
)
5 15 25 35 45 55 65 75 85 95
0
10
20
30
40
50
60
70
80
90
100
Pa
tie
nt
s 
(n)
Predicted mortality (%)
MPM III SAPS 3 SAPS 3 - CSA
Figure 1 |Calibration curves for MPM0-III (black solid line),
SAPS 3 – general equation (dotted black line) and SAPS 3
customized for South America (solid gray line). Dotted thin
gray line represents the observed mortality. Columns denote the
number of patients in each stratum. MPM0, Mortality Probability
Models; SAPS, Simplified Acute Physiology Score.
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external validation of prognostic models for critically ill
patients requires substantial sample sizes.31,32 With few
exceptions,10,12,19,21 studies evaluating prognostic scores in
patients with AKI are limited by their sample sizes.9,20,22,23,29
Therefore, the results of discrimination and calibration in our
study and in the study of Tsai et al.29 must be interpreted
with caution. Certainly, our results deserve to be validated in
a larger multicenter study. Finally, we have chosen not to
collect data to estimate the scores at ICU admission, because
we believe we have solid arguments that the measurement of
such parameters in clinical studies on this particular
subgroup of patients may be more appropriate at the start
of RRT, instead of ICU admission.
In conclusion, the SAPS 3 prognostic model at the start of
RRT was accurate in predicting hospital mortality in our
cohort of critically ill patients with AKI in need of RRT. More
precise estimations of mortality in these patients are welcome
as they can be helpful to enroll patients in clinical studies.
Nevertheless, it should be stressed that no prognostic model
should be used as a single parameter to guide decisions
related to patient’s care and cost containments.
MATERIALS AND METHODS
Design and setting
This was a prospective observational study conducted at 11 ICUs of
three tertiary care hospitals in Rio de Janeiro, Brazil. The ethics
committees of all institutions approved the study and the need for
informed consent was waived.
Selection of participants, data collection, and definitions
From January 2007 to July 2008, every patient admitted to the
participating ICUs with AKI in need for RRT was studied. Either
patients with AKI or acute on chronic kidney injury were evaluated.
Patients with non-renal indications for RRT (n¼ 0), end-stage renal
disease requiring chronic dialysis (n¼ 22), those with ICU stay
o24 h (n¼ 12) and readmissions (n¼ 8) were not considered.
AKI was classified according to the RIFLE criteria33 immediately
before the start of RRT. Decisions to start, change the method, and
cease RRT were taken together by the nephrologist and the
intensivist responsible for the patient on an individual basis.
Patients were managed by the same team of nephrologists in all
participating ICUs. Prescribed RRT modes were daily conventional
dialysis, daily extended dialysis and continuous RRT (CRRT) taking
into consideration patient’s hemodynamic status, being CRRT
employed in patients receiving vasoactive drugs and in those with
potential for hemodynamic instability. RRT procedures were
performed using FAD 100 (Braun, Rio de Janeiro, Brazil) and
Prisma or AK series (Gambro) machines, and polissulfone (F series,
Table 4 |Multivariate models of the predictive factors for increased hospital mortality at the start of RRT in patients with AKI
(n=244)a
Variables b-Coefficient Odds ratio (95% CI) P-value
Model including SAPS 3 CSA
SAPS 3 CSA 0.053 1.065 (1.046–1.083) o0.001
ICU stay before RRT (days) 0.063 1.055 (1.020–1.091) 0.002
Constant 3.538
AROC=0.83 (95% CI, 0.78–0.89); Goodness-of-fit test, (w2=7.405, P=0.494)
Model including MPM0-III
MPM0-III 0.065 1.067 (1.037–1.099) o0.001
ICU stay before RRT (days) 0.053 1.054 (1.018–1.091) 0.003
Vasopressors 1.263 3.537 (1.707–7.326) 0.001
Charlson Index X 1 point 1.043 2.837 (1.236–6.514) 0.014
Chronic renal failure 0.680 0.507 (0.225–1.139) 0.099
Constant 3.538
AROC=0.81 (95% CI, 0.75–0.87); Goodness-of-fit test, (w2=10.742, P=0.217)
AKI, acute kidney injury; AROC, area under receiver-operating characteristic curve; CI, confidence interval; CSA, customized equation for countries from Central and South
America; ICU, intensive care unit; RRT, renal replacement therapy; SAPS, Simplified Acute Physiology Score.
aThe observed hospital mortality was 68.4%.
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Fresenius) and AN69S (Gambro) membranes. Customized dialysis
and replacement solutions were prescribed on a daily basis aiming to
optimize patient’s metabolic control and were produced at the
hospital pharmacy as appropriate.
Demographic, clinical and laboratory data were prospectively
collected. Variables used in the calculation of SAPS 316 and
MPM0-III
18 scores were collected at the start (±1 h) of RRT in all
patients. The most disturbed values were assigned for vital signs and
laboratory data as recommended by each score. For sedated patients,
estimated Glasgow coma scale before sedation was used. Zero points
or reference values were considered for missing variables.16,18 There
were no missing variables for clinical and physiological data. Among
laboratory variables, normal values were attributed only for
bilirubin in 71 (29%) patients. No patient with jaundice on physical
examination was lacking serum bilirubin dosage. The predicted
mortality of SAPS 3 score derived from customized equation for
CSA was also estimated.16 Patients were classified based on the
reason for ICU admission in medical, scheduled surgical, and
emergency surgical. Previous comorbidities, previous health sta-
tus,34 main diagnosis for ICU admission, pre-morbid renal function,
need for mechanical ventilation and vasopressors for more than 24 h
and contributing factors for AKI were also recorded. The
measurement of comorbidities was performed using the Charlson
Comorbidity Index.35 Oliguria was defined as urine output
o400 ml/day. Sepsis was diagnosed as recommended by the
Consensus Conference of The American College of Chest Physicians
and Society of Critical Care Medicine.36 Hospital mortality was the
outcome variable of interest. End-of-life decisions (to withhold or
withdraw life-sustaining therapies) were taken in patients who did
not recover from the acute illness despite full ICU care.
Data management and statistical analysis
Data were entered in a computer database by a single data manager.
Data consistency was assessed by a single author (MS) through a
rechecking procedure of a 10% random sample of patients. All
documented data were also evaluated for implausible and outlying
values. Continuous variables were presented as mean±s.d. or
median (25–75% interquartile range). Categorical variables were
reported as absolute numbers (frequency percentages) and analyzed
by w2 test (with Yates correction where applicable). Discrimination
was evaluated by calculating the AROC.37 The Hosmer–Lemeshow
goodness-of-fit test C statistic was used to evaluate the agreement
between the observed and expected number of survivors and non-
survivors across all of the strata of probabilities of death
(calibration).38 A high P-value (40.05) would indicate a good fit
for the model. Calibration curves were constructed by plotting
predicted mortality rates stratified by 10% intervals of mortality risk
(x axis) against observed mortality rates (y axis). SMR with
respective 95% confidence intervals were calculated for each model
by dividing the observed mortality rates by the predicted mortality
rates. AROC were compared using nonparametric statistics.39
Univariate analysis was used to identify factors associated with
hospital mortality. Univariate and multivariate logistic regression
were used to identify factors associated with hospital mortality.
Linearity between continuous variables and the dependent variable
was shown using locally weighted scatterplot smoothing.38 Variables
yielding P-values below 0.2 by univariate analysis were entered into a
forward multivariate logistic regression analysis. Multivariate
analysis results were summarized by estimating odds ratios and the
respective 95% confidence intervals. Possible interactions were tested.
A two-tailed P-value o0.05 was considered statistically significant.
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